Yifan Xinfu Pharmaceutical Co Ltd - Asset Resilience Ratio
Yifan Xinfu Pharmaceutical Co Ltd (002019) has an Asset Resilience Ratio of 0.53% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Yifan Xinfu Pharmaceutical Co Ltd (002019) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2023)
This chart shows how Yifan Xinfu Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See Yifan Xinfu Pharmaceutical Co Ltd (002019) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Yifan Xinfu Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Yifan Xinfu Pharmaceutical Co Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥65.00 Million | 0.53% |
| Total Liquid Assets | CN¥65.00 Million | 0.53% |
Asset Resilience Insights
- Limited Liquidity: Yifan Xinfu Pharmaceutical Co Ltd maintains only 0.53% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Yifan Xinfu Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Yifan Xinfu Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AbbVie Inc
NYSE:ABBV |
Drug Manufacturers - General | 0.02% |
|
Roche Holding AG
SW:ROG |
Drug Manufacturers - General | 15.37% |
|
Biogen Inc
NASDAQ:BIIB |
Drug Manufacturers - General | 2.74% |
|
CSPC Pharmaceutical Group Limited
F:CVG |
Drug Manufacturers - General | 4.64% |
|
AstraZeneca PLC
LSE:AZN |
Drug Manufacturers - General | 0.03% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3 |
Drug Manufacturers - General | 10.10% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
Annual Asset Resilience Ratio for Yifan Xinfu Pharmaceutical Co Ltd (2015–2023)
The table below shows the annual Asset Resilience Ratio data for Yifan Xinfu Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.65% | CN¥75.01 Million ≈ $10.98 Million |
CN¥11.50 Billion ≈ $1.68 Billion |
-0.11pp |
| 2022-12-31 | 0.76% | CN¥95.50 Million ≈ $13.97 Million |
CN¥12.54 Billion ≈ $1.84 Billion |
-2.86pp |
| 2021-12-31 | 3.62% | CN¥440.39 Million ≈ $64.44 Million |
CN¥12.17 Billion ≈ $1.78 Billion |
+3.22pp |
| 2020-12-31 | 0.40% | CN¥46.73 Million ≈ $6.84 Million |
CN¥11.71 Billion ≈ $1.71 Billion |
+0.05pp |
| 2019-12-31 | 0.35% | CN¥39.00 Million ≈ $5.71 Million |
CN¥11.07 Billion ≈ $1.62 Billion |
-1.03pp |
| 2018-12-31 | 1.39% | CN¥135.58 Million ≈ $19.84 Million |
CN¥9.77 Billion ≈ $1.43 Billion |
-6.37pp |
| 2017-12-31 | 7.76% | CN¥680.00 Million ≈ $99.51 Million |
CN¥8.77 Billion ≈ $1.28 Billion |
+4.93pp |
| 2016-12-31 | 2.83% | CN¥197.50 Million ≈ $28.90 Million |
CN¥6.98 Billion ≈ $1.02 Billion |
+1.79pp |
| 2015-12-31 | 1.03% | CN¥47.00 Million ≈ $6.88 Million |
CN¥4.55 Billion ≈ $665.33 Million |
-- |
About Yifan Xinfu Pharmaceutical Co Ltd
Yifan Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products, raw materials, and polymer materials in Southeast Asia, Europe and North America, Singapore, South Korea, Italy, China, Germany, and the United States. It offers Chinese patent medicines, chemical medicines and biological medicines; and vitamin products, including vitamin B5 an… Read more